Southampton ophthalmologist is taking part in a £5 million study Banner overlay

Stargardt’s treatment trial reaches the UK

Southampton ophthalmologist is taking part in a £5 million study with a drug that is hoped will treat the sight threatening condition

10 Feb 2018 by Emily McCormick

Researchers in South of England will become the first in the UK to trial a new drug that could prevent sight loss caused by a currently untreatable condition, the University Hospital Southampton NHS Trust has revealed.

Consultant ophthalmologist, Professor Andrew Lotery, is part of a £5m study of remofuscin, a drug that is being explored in relation to Stargardt’s disease.

Stargardt‘s disease affects the macula and causes a reduction in central vision. It is a form of juvenile macular degeneration and affects around one in 10,000 children.

While there is currently no treatment for the condition, Professor Lotery joins the new study with colleagues from centres in the Netherlands, Italy, Germany and Norway.

Speaking about the new trial, Professor Lotery said: “There is no approved treatment available for Stargardt’s, so we are very excited about the opportunity to test remofuscin and offer these patients the hope that we may be able to stop the progression of the condition.”

Professor Carel Hoyng, who is a specialist in inherited retinal diseases at Radboud University Medical Center in the Netherlands and is the study’s principal investigator, added: “This drug’s potential goes beyond existing approaches. So far the attempt was to keep lipofuscin levels the same, but remofuscin has been shown to actually remove existing lipofuscin in pre-clinical models and this may result in significant patient benefit.”

The study has received funding from the European Commission’s H2020 programme. Professor Lotery’s work in Southampton is supported by Gift of Sight, a charity that was established in 2004 to raise money for research into the treatment of complex eye disease.


Your comments

You must be logged in to join the discussion. Log in

Comments (0)